Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T20:04:05.031Z.
Calculation as of: 2026-10-06T20:04:05.031Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 24a0b8a5defa6360a8df5348432e42fec2fdf5a1d44ff9a0d63a76d612d48360
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Replimune Group, Inc.
Market Cap
$1.11B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.11B
Operating Cash Flow Yield
N/A
TTM Avg
1.44%
3Y Avg
1.04%
5Y Avg
1.44%
Market Cap
$1.10B
Operating Cash Flow Yield
N/A
TTM Avg
2.62%
3Y Avg
1.63%
5Y Avg
1.24%
Market Cap
$1.13B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
Operating Cash Flow Yield
0.55%
TTM Avg
1.29%
3Y Avg
0.78%
5Y Avg
1.14%
Market Cap
$1.10B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
Operating Cash Flow Yield
17.78%
TTM Avg
18.66%
3Y Avg
11.11%
5Y Avg
8.71%
Market Cap
$1.09B
Operating Cash Flow Yield
N/A
TTM Avg
3.56%
3Y Avg
3.24%
5Y Avg
2.72%
Market Cap
$1.09B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Replimune Group, Inc. (REPL) | $1.11B | N/A | N/A | N/A | N/A |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | N/A | 1.44% | 1.04% | 1.44% |
| STAAR Surgical Company (STAA)vs › | $1.10B | N/A | 2.62% | 1.63% | 1.24% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 0.55% | 1.29% | 0.78% | 1.14% |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.10B | N/A | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.13B | 17.78% | 18.66% | 11.11% | 8.71% |
| OPKO Health, Inc. (OPK)vs › | $1.09B | N/A | 3.56% | 3.24% | 2.72% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 2.50% | 2.27% | 2.68% | 2.53% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
